Idexx Laboratories Inc's Cash & cash equivalent grew by 0.31 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Idexx Laboratories Inc's Quick Ratio to 0.16, Quick Ratio remained below Idexx Laboratories Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher Quick Ratio than Idexx Laboratories Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 3013 to 3420.

Explain Quick Ratio?
How much Cash & cash equivalents IDXX�s has?
What are IDXX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IDXX/financial-strength

https://api.csimarket.com/api/v1/companies/IDXX/fundamentals

https://api.csimarket.com/api/v1/companies/IDXX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

IDXX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	0.99 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-5.11 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.16	Subscribe	Subscribe	Subscribe	Subscribe
IDXX's Total Ranking	# 3420	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-1.82 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	0.31 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 14
Healthcare Sector	# 828
Overall Market	# 3420

Quick Ratio Statistics
High	Average	Low
0.92	0.38	0.09
(Mar 31 2011)		(Sep 30 2022)

Financial Statements
Idexx Laboratories Inc's Current Liabilities	$ 1,264 Millions	Visit IDXX's Balance sheet
Idexx Laboratories Inc's Cash & cash equivalent	$ 198 Millions	Visit IDXX's Balance sheet
Source of IDXX's Sales		Visit IDXX's Sales by Geography

Cumulative Idexx Laboratories Inc's Quick Ratio

IDXX's Quick Ratio for the trailling 12 Months

IDXX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	8.75 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-6.05 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.15	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3046	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	0.24 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-1.35 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to IDXX Financial Strength Comparisons >> Go to Compare IDXX Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the decrease in Current Liabilities in the Q3 2026 to $1,264.22 millions, cumulative Quick Ratio remained unchanged at 0.15 below the Idexx Laboratories Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Idexx Laboratories Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 4101 to 4135.

Explain Quick Ratio?
How much Cash & cash equivalents IDXX�s has?
What are IDXX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 910
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.52	0.29	0.09
(Sep 30 2014)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Neogen Corporation	0.19	$ 172.000 Millions	$ 899.100 Millions
Idexx Laboratories Inc	0.16	$ 197.536 Millions	$ 1,264.222 Millions
Quidelortho Corp	0.16	$ 166.400 Millions	$ 1,067.100 Millions

Date modified: 2026-11-03T10:00:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.